Table 4

Improved endurance performance and disease activity after 12 weeks of endurance exercise in myositis patients.

Patient

Group

MMT

0 to 80

HAQ

0.00 to 3.00

s-CPK

μcat/l

Physician's

global disease activity

VAS

0 to 100

Patient's

global disease activity

VAS

0 to 100

Mitax

0.00 to 1.00

Cycling

time minutes


EG/CG

0w

12w

0w

12w

0w

12w

0w

12w

0w

12w

0w

12w

0w

12w


A†

EG

79

79

0.00

0.25

6.2

1.2

5

0

3

1

0.05

0.00

18

31‡

B†

EG

70

75

0.50

0.38

2.2

1.9

4

0

72

5

0.11

0.07

8

55‡

C†

EG

75

77

0.25

0.00

1.8

1.3

0

0

9

0

0.24

0.19

15

37‡

D†

EG

76

80

0.38

0.00

4.2

2.3

0

0

0

9

0.10

0.06

25

30‡

E

EG

42

57‡

NA

1.63

6.8

5.2

NA

3

NA

43

0.02

0.22

13

20‡

F†

EG

76

75

0.50

0.50

NA

NA

14

0

15

0

0.16

0.04

15

50‡

G

EG

71

76

0.38

0.38

1.5

2.0

3

0

32

11

0.00

0.00

10

15‡

H

EG

76

78

0.50

0.50

1.0

1.1

11

7

54

53

0.06

0.02

20

40‡

I†

EG

77

77

1.38

0.63

1.3

1.3

10

3

24

13

0.11

0.02

15

25‡

J

CG

77

77

0.38

0.63

1.6

3.1

0

0

44

26

0.19

0.11

9

10

K†

CG

72

74

0.38

0.00

1.8

1.8

1

0

13

5

0.06

0.10

15

15

L

CG

66

73

0.50

0.13

1.3

1.2

0

0

77

52

0.09

0.21

15

15

M

CG

75

70

0.50

0.38

3.7

1.9

3

5

20

44

0.14

0.13

20

20

N

CG

57

75‡

1.75

2.00

NA

NA

NA

5

59

69

NA

0.24

8

8

O

CG

75

72

0.63

0.88

1.2

1.6

10

6

39

59

0.13

NA

15

19‡


Individual results in myositis core set measures for disease activity and endurance performance (cycling time) before and after training (exercise group) or in the non-exercising control group. Data are analyzed by criteria for minimal clinical improvement set for patients with polymyositis and dermatomyositis [32]. 0 w, baseline assessment; 12 w, follow-up assessment; CG, control group (n = 6); EG, exercise group (n = 9); HAQ, health assessment questionnaire; MITAX, myositis intention to treat activity index; MMT, manual muscle test; NA, not assessed; s-CPK, creatine phosphokinase, (normal values <2.5 μcat/l in women, <3.0 μcat/l in men). Classification of improvement in disease activity measures: †, improved compared to baseline by ≥20% in ≥50% of measures with no more than two worsened by ≥25%, which cannot include MMT. ‡, improved muscle function (MMT/cycling time) compared to baseline by ≥ 20%.

Alemo Munters et al. Arthritis Research & Therapy 2013 15:R83   doi:10.1186/ar4263

Open Data